Myocarditis: Still Rare But A Serious Threat For Young Males After mRNA COVID-19 Vaccine

Myocarditis: Still Rare But A Serious Threat For Young Males After mRNA COVID-19 Vaccine

The risk of myocarditis among males aged 16 to 19 years after receiving the third dose of the Pfizer-BioNTech COVID-19 vaccine was found to be approximately 1 in 15,000, and the cases were rare and mild, finds a new study published today in the journal Circulation. Several previous reports and studies from public health agencies around the world, […]

The post Myocarditis: Still Rare But A Serious Threat For Young Males After mRNA COVID-19 Vaccine appeared first on Revyuh.